Influenza immunisation research hub

Randomized, Observer-Blind, Active-Controlled, Phase III Study in Adults ≥ 60 years of Age to Assess the Safety and Immunogenicity of Abbott’s Candidate High-Dose Influenza Vaccine.

This study tests a new high-dose flu vaccine designed for older adults. As we age, our immune systems need extra help to fight off illness. Researchers want to see if this new jab safely creates strong protection against three flu strains compared to existing flu vaccines.